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ABSTRACT
Introduction: Resistance to antiretroviral drugs can complicate the management of HIV-1
infection and impair control of its spread. The aim of the current study was to investigate the
prevalence and transmission of HIV-1 drug resistance among 106 antiretroviral therapy (ART)-
naïve patients diagnosed in Iceland (1996–2012).
Methods: HIV-1 polymerase sequences were analysed using the Calibrated Population
Resistance tool. Domestic spread of transmitted drug resistance (TDR) was investigated
through maximum likelihood and Bayesian approaches.
Results: Among ART-naïve patients, the prevalence of TDR to any of the following classes
(NRTIs, NNRTIs and PIs) was 8.5% (95% CI: 4.5%- 15.4%): 6.6% to NRTIs, 0.9% to NNRTIs, and
1.9% to PIs. The most frequent NRTI mutation detected was T215C/D (n=7, 5.7%). The only
NNRTI mutation detected was K103N (n=1, 0.9%). PI mutations detected were M46I (n=1,
0.9%) and L90M (n=1, 0.9%). Six patients harbouring T215C/D, were linked in a supported
phylogenetic cluster. No significant association was found between TDR and demographic or
risk groups. Trend analysis showed a decrease in the prevalence of TDR (1996–2012, p=0.003).
Conclusions: TDR prevalence in Iceland was at a moderate level and decreased during 1996-
2012. Screening for TDR is recommended to limit its local spread and to optimize HIV-1
therapy.
Abbreviations: ART: Anti-retroviral therapy; ARV: antiretroviral; ATV/r: atazanavir/ritonavir;
AZT: azidothymidine; BEAST: Bayesian evolutionary analysis by sampling trees; CI: confidence
interval; CPR: calibrated population resistance; CRF: circulating recombinant form; d4T: sta-
vudine; EFV: efavirenz; FET: Fishers’ exact test; FPV/r: fosamprenavir/ritonavir; HET: hetero-
sexual; IDU: injection drug use; IDV/r: indinavir/ritonavir; LPV/r: lopinavir/ritonavir; MSM: men
who have sex with men; M-W: Mann–Whitney U test; NFV: nelfinavir; NNRTIs: non-nucleoside
reverse transcriptase inhibitors; NRTIs: nucleoside reverse transcriptase inhibitors; NVP: nevir-
apine; PIs: protease inhibitors; pol: polymerase gene; SDRM: surveillance drug resistance
mutation; SQV/r: saquinavir/ritonavir; TDR: transmitted drug resistance
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HIV-1 was first reported in Iceland in 1985. By the
end of 2012 a total of 300 patients had been diag-
nosed with HIV-1 infection in the country, of which
66 had developed AIDS and 39 passed away as a
result of the disease.[1,2] Following the first introduc-
tion of HIV-1 to Iceland onwards to the end of 2012,
the infection has been dominated by clade B with a
relatively low fraction of founders compared to the
total number of introductions.[3] HIV-1 infection in
the country appeared to be highly concentrated
among men who have sex with men (MSM) and
injection drug users (IDUs) and less among hetero-
sexuals (HET). The genetic diversity of HIV-1 in
Iceland has increased significantly over time, most
likely related to the increased proportion of foreign-
born residents in the country from the mid-
1990s.[3,4]
Successful management of HIV-1 infected patients
is highly dependent on antiretroviral therapy (ART)
that has been shown to reduce morbidity and mor-
tality from the disease.[5] ART also contributes to the
prevention of HIV-1 spread, as lowering the viral
load diminishes the risk of HIV-1 transmission.[6–8]
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Antiretroviral (ARV) drug resistance mutation can
arise as a result of direct transmission from a patient
harbouring drug-resistant mutants (primary or trans-
mitted drug resistance, TDR) or due to selection of
drug-resistant mutants within patients who are not
successfully managed (secondary or acquired resis-
tance). The rapid evolution of HIV-1 facilitated by
its error-prone reverse transcriptase and selection
pressure by the ARV drugs are the driving forces
behind the emergence of ARV drug resistance.[9,10]
Resistant strains can be transmitted, causing early
treatment failures in the newly infected individuals.
Thus, TDR jeopardizes both preventive and treat-
ment efforts in patients.[11] Acquired resistance can
emerge when the treatment regimens fail to suppress
the viral load, most commonly due to suboptimal
adherence of the patients. Patients with ARV resistant
mutants are at high risk of treatment failure with risk
of forward transmission of these mutant variants.[12–
14] Therefore, WHO highly recommends testing
patients who are newly diagnosed with HIV-1 infec-
tion for ARV drug resistance.[15]
No earlier studies have investigated the status of
ARV drug resistance in Iceland. The objectives of the
current study were to conduct an epidemiological
surveillance on TDR among patients who were diag-
nosed with HIV-1 infection in Iceland between 1996
and 2012 and to describe the types of resistance to
different classes of ARV drugs in the country, as well
as to investigate the domestic transmission of TDR.
Materials and methods
Study population
Iceland is a Nordic country with a population of about
320,000 people as of the end of 2012.[2] The study
comprised 106 HIV-1 infected patients diagnosed in
Iceland during 1996–2012. Limited availability of con-
current plasma samples from patients diagnosed prior
to 1996 precluded the inclusion of such patients in the
study. Patient data included age, sex, self-reported risk
factor, country of birth and self-reported country of
infection. HIV-1 subtype/circulating recombinant
form (CRF) data were obtained from a previous
work that included our study population.[3] The
inclusion criteria were as follows: (1) patients newly
diagnosed with HIV-1 infection; (2) plasma samples
drawn within six months of diagnosis. The exclusion
criteria were as follows: (1) known exposure to ART
based on medical records or self-reporting; (2) pre-
vious diagnosis of HIV-1 infection outside Iceland.
Ethical approval
The study was approved by Landspitali University
Bioethics Committee in accordance with the
declaration of Helsinki. Since many patients at the
time of our study initiation were deceased or had
moved outside Iceland, the Landspitali University
Hospital Ethics Committee considered the use of
the study material for the research in this study with-
out the need of consent of the study participants
since it would be impossible or impractical to obtain.
Genotypic HIV-1 resistance testing
The HIV-1 polymerase (pol) sequences that were
utilized in our study were generated using the
Sanger population sequencing method. The details
of the sequencing approach were described pre-
viously.[3] The 106 partial pol sequences (1020 base
pairs; nucleotide positions 2268–3287 of HXB2,
GenBank accession number K03455) were analysed
using the calibrated population resistance (CPR) tool
in the Stanford University HIV drug resistance data-
base (http://cpr.stanford.edu/cpr.cgi).[16] The 2009
Stanford Surveillance Drug Resistance Mutation list
include the following codon sites in the protease
region: 23, 24, 30, 32, 46, 47, 48, 50, 53, 54, 73, 76,
82, 83, 84, 85, 88, 90, and the following codon sites in
the reverse transcriptase region: 41, 65, 67, 69, 70, 74,
75, 77, 100, 101, 103, 106, 115, 116, 151, 179, 181,
184, 188, 190, 210, 215, 219, 225, 230.[16]
Maximum likelihood phylogenetic analysis
A maximum likelihood (ML) phylogenetic tree was
constructed for the Icelandic subtype B sequences
(n = 63) in GARLI v2.0 using the GTR+I + Γ nucleotide
substitution model.[17] Statistical support was deter-
mined using approximate likelihood ratio test
Shimodaira–Hasegawa (aLRT SH-like) in PhyML v3.1,
and aLRT-SH values of more than or equal to 0.9 were
considered significant.[18,19] Five runs in GARLI were
conducted and the tree with the highest likelihood value
was retained for analysis. The ML analysis was repeated
after removal of resistance codon positions in the pro-
tease region (30, 32, 46, 47, 48, 50, 54, 82, 84, 88 and 90)
and in the reverse transcriptase region (41, 62, 65, 67,
70, 74, 75, 77, 100, 101, 103, 106, 108, 115, 116, 151, 181,
184, 188, 190, 210, 215, 219, 225, 227 and 230) to reduce
potential bias due to ARV selective pressure.[20]
Following removal of aforementioned sites, the
sequence alignment had a length of 909 base pairs.
Bayesian phylogenetic analysis
The Icelandic clade B sequences were analysed
using a Bayesian approach in BEAST v1.8.2.[21]
Analysis was done using a constant coalescent
population model with relaxed lognormal uncorre-
lated molecular clock with an uninformative rate
prior and HKY85 nucleotide substitution model
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(Supplementary File 1). Five runs, each of 100 mil-
lion steps in the Markov chain, were performed
using BEAST and then combined using
LogCombiner v1.8.2 in BEAST package.[21]
Convergence was checked using Tracer v1.6.0
(http://beast.bio.ed.ac.uk/Tracer), and BEAST para-
meters showed high convergence with effective sam-
ple size (ESS) values ≥ 200 for all. The maximum
clade credibility (MCC) tree was generated using
TreeAnnotator v1.8.0 available in BEAST package.
[21] For branch support, posterior probability (PP)
values equal to 1.0 were considered significant. The
analysis was repeated after removal of resistance
codon positions as described previously.
Statistical analysis
The binomial distribution (Wilson score interval)
95% confidence interval of the prevalence was calcu-
lated using EpiTools epidemiological calculator avail-
able online (http://epitools.ausvet.com.au). P-values
were calculated using the exact two-sided Fisher’s
test (FET) through GraphPad Software, Inc., available
online (http://graphpad.com/quickcalcs/contin
gency1/). Mann–Whitney U test (M-W) was done
using the VassarStats website, available online
(http://vassarstats.net/utest.html). For trend analysis,
we used two-tailed linear-by-linear test for associa-
tion through IBM SPSS Statistics 21.0.
Sequence accession numbers
We have selected 30 partial pol sequences included in
this study to be deposited in GenBank. These
sequences were assigned with the following accession
numbers: KY084400–KY084429.
Results
Characteristics of the study population
Out of 209 patients who were diagnosed with HIV-1
infection in Iceland during 1996–2012, 106 had sam-
ples which met the inclusion criteria of the study and
were included for subsequent analysis. The character-
istics of the study subjects are illustrated in Table 1.
Approximately 60% of the patients were males and
40% were females. The median age at the time of
diagnosis was 34 years (range: 2–77 years). Males
were found to be significantly older than females
(median age 37 vs. 30 years, respectively, p < 0.001,
M-W). The median time between diagnosis and sam-
pling was seven days (range: 0–154 days).
Self-reported routes of HIV-1 infection were: HET
(n = 45; 42%), MSM (n = 29; 27%) and IDU (n = 26;
25%). A high proportion of the patients (n = 65; 61%)
were born in Iceland, and approximately 50% of all
patients reported to have been infected outside the
country.
The distribution of the study participants in terms
of sex and risk factor for HIV-1 acquisition was
nearly matched with the total number of diagnosed
patients during the same period. The exception was
the (unknown/others) risk factor category, which was
under-represented in our sample (Table 2). To
exclude selection bias in samples with regard to year
of diagnosis, we compared the total number of indi-
viduals who were diagnosed with HIV-1 infection to
the number of samples that were analysed by dividing
the study period into two time intervals, 1996–2004
and 2005–2012. Similar proportions of sampling were
found for the intervals (50.6% vs. 50.7%).
Distribution of HIV-1 subtypes/CRFs
Subtype B was found to be the most common genetic
variant in the study sample (n = 63; 59%) followed by
Table 1. Characteristics of the HIV-1 infected indi-




















an: number; bRisk factor: Self-reported risk factor for HIV-1
acquisition (MSM: men who have sex with men; HET:
heterosexual; IDU: injection drug use; MTCT: mother to
child transmission; cCountry of infection: self-reported
country of infection.
Table 2. Distribution of the study subjects compared to the
total population of patients who were diagnosed during the
same time interval.
Study subjects Total population Coverage
Characteristic na % n % %
Total 106 209 51
Sex
Male 64 60 134 64 48
Female 42 40 75 36 56
Risk Factorb
MSM 29 27 48 23 60
HET 45 42 81 39 56
IDU 26 25 45 22 58
Others/unknown 6 6 35 17 17
an: number; bRisk factor: self-reported risk factor for HIV-1 acquisition
(MSM: men who have sex with men; HET: heterosexual; IDU: injection
drug use; Others: mother to child transmission, blood transfusion.
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CRF01_AE (n = 13; 12%), subtype C (n = 10; 9%),
CRF02_AG (n = 8; 8%) and sub-subtype A1 (n = 6;
6%). The minor subtypes/CRFs included: subtype D
(n = 2), CRF14_BG (n = 1), CRF16_A2D (n = 1),
CRF40_BF (n = 1) and CRF45_cpx (n = 1). For
subsequent analysis related to subtypes/CRFs, we
have divided the samples into subtype B (n = 63)
and non-B subtypes/CRFs (n = 43) groups.
Transmitted drug resistance (TDR)
The prevalence of ARV drug resistance among the
study population to any of the following classes:
nucleoside reverse transcriptase inhibitor (NRTI),
non-nucleoside reverse transcriptase inhibitor
(NNRTI) and protease inhibitor (PI), was found to
be 8.5% (95% CI: 4.5%–15.4%). In the nine patients
that harboured ARV drug resistance mutations, seven
had at least one mutation suggestive of resistance to
NRTIs, two patients had at least one mutation indi-
cative of resistance to PIs and one patient had a
mutation indicative of resistance to NNRTIs. A single
patient had mutations suggestive of resistance to both
NRTIs and PIs. None of the patients had a sequence
with mutations to all three classes of ARV drugs.
Thymidine analogue 215 revertant mutants
(T215C/D), that cause low-level resistance to azi-
dothymidine (AZT) and stavudine (d4T), dominated
the NRTI mutations detected (n = 7; 6%). The other
NRTI mutation detected was M41L (n = 1; 0.9%),
which causes intermediate resistance to AZT and
d4T. The only major NNRTI mutation detected was
K103N (n = 1; 0.9%), which causes high-level resis-
tance to efavirenz (EFV) and nevirapine (NVP). The
two major PI mutations found were M46I (n = 1;
0.9%), which causes low-level resistance to nelfinavir
(NFV) and L90M (n = 1; 0.9%), which causes high-
level resistance to NFV, intermediate resistance to
indinavir/ritonavir (IDV/r) and saquinavir/ritonavir
(SQV/r) and low-level resistance to atazanavir/rito-
navir (ATV/r), fosamprenavir/ritonavir (FPV/r) and
lopinavir/ritonavir (LPV/r).[16]
The prevalence of TDR was higher in patients who
were born in Iceland (12.3% vs. 2.5%), and in patients
who reported infection in Iceland (10.2% vs. 2%);
however, the difference was not statistically signifi-
cant. Stratified by risk factor, TDR was found to have
a higher prevalence in HET (11.1%) and MSM
(10.3%) in comparison to IDU (3.8%) but without
statistical significance. TDR was also more prevalent
among patients infected with subtype B compared to
all non-B subtypes/CRFs (12.7% vs. 2.3%) but also
without statistical significance (Table 3).
Maximum likelihood analysis revealed that six
out of eight subtype B sequences, which harboured
TDR mutations, were part of a single phylogenetic
cluster with high statistical support (aLRT-SH like
value of 1.0). The patients within this cluster har-
boured T215C/D and were diagnosed between 1997
and 2008. Three patients were males, two of whom
reported MSM and one reported HET as risk fac-
tors for HIV acquisition. Three patients were
females who reported HET as a risk factor for
HIV acquisition. An identical cluster was found in
the ML tree constructed after removal of resistance
mutation codon sites. This excludes the possibility
of incorrect clustering due to convergent evolution.
The same transmission cluster was also identified
through Bayesian analysis before and after removal
of resistance mutation codon sites, with a PP value
of 1.0 in the MCC tree (Figure 1). The time to the
most recent common ancestor of the cluster har-
bouring (T215C/D) dated back to 1989 (median
estimate, 95% highest posterior density interval:
1983–1994).
Temporal trend of TDR
When we compared patients diagnosed before mid-
2004 (n = 40) to those with dates of diagnosis after
mid-2004 (n = 66), we found a significant higher
likelihood of harbouring drug resistance mutations
in the earlier time interval (p = 0.025, FET).
To investigate the trend of TDR prevalence and
subtype distribution over time, we divided the study
period into quarters, each of which represented
4.25 years. The proportion of patients with TDR was
26.0, 5.9, 4.0 and 2.4% for the four quarters, respec-
tively. A significant decline of TDR prevalence was
noted during 1996–2012 (p = 0.003; LBL, Figure 2).
However, the decrease of TDR did not display a sig-
nificant change over the latter three quarters (April
Table 3. Characteristics of ART-naive patients with and with-
out TDR.
TDRa Non-TDR p-value
nb % n % TDR vs. non-TDR
Patients no. 9 97
Sex
Male 5 56 59 61 1.00
Female 4 44 38 39
Risk factor
MSM c 3 33 26 27 MSM vs. HET: 1.00
HET d 5 56 40 41 HET vs. IDU: 0.40
IDU e 1 11 25 26 MSM vs. IDU: 0.61
MTCT f 0 0 1 1
Unknown 0 0 5 5
Country of birth
Iceland 8 89 57 59 0.15
Non-Iceland 1 11 40 41
Reported country of Infection
Iceland 6 50 37 34 0.16
Non-Iceland 2 17 59 54
Unknown 4 33 14 13
Subtype
B 8 89 55 57 0.08
Non-B 1 11 42 43
aTDR: transmitted drug resistance; bn: number; cMSM: men who have sex
with men; dHET: heterosexual; eIDU: injection drug use; fMTCT: mother-
to-child-transmission.
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2000–December 2012, p = 0.518; LBL). No statistical
difference was found upon tracking the temporal
changes in subtype B vs. non-B subtypes/CRFs over
the study period (p = 0.493; LBL).
Discussion
In the current study, we assessed the prevalence of
TDR among HIV-1 infected, ART-naive patients in
Iceland over a period of 17 years. By sampling 51% of
known infections during the same period, represen-
tative of different patient categories, we were able to
estimate the prevalence of TDR in the country with
reasonable accuracy.
The prevalence of TDR in Iceland was found to be
at a moderate level (8.5%). This result is slightly
higher compared to other Nordic countries.[22,23]
Nevertheless; our prevalence estimate was within the
Figure 1. Time-resolved maximum clade credibility tree of 63 subtype B Icelandic sequences. The tree was constructed using
TreeAnnotator v1.8.0 included in BEAST software package. Branches with posterior probability value of 1.0 are marked with an
asterisk. Terminal branches marked with a black circle at the tip represent sequences harbouring at least one transmitted drug
resistance (TDR) mutation. The grey shaded area represents the monophyletic cluster with TDR mutation (T215C/D).
Figure 2. Temporal trend of transmitted drug resistance (TDR) over the study period. The horizontal axis represents the study
period divided into four quarters, each of which represents 4.25 years. The vertical axis represents proportion of TDR in each
quarter. The p-value indicates the result of trend analysis conducted using linear-by-linear test for association.
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range reported in recent studies which investigated
the prevalence of TDR in other Western European
countries.[24–26] The inclusion of patients diagnosed
in the 1990s might have influenced our prevalence
estimate. As it is known that the increased ART
options together with refined knowledge and
improved surveillance have resulted in decreasing
levels of resistance,[27] the prevalence of TDR was
significantly lower among patients who were diag-
nosed in the latter half of the study period.
The results of our study have also shown an evi-
dence of decreasing TDR prevalence in Iceland dur-
ing 1996–2012. This can be attributed to the
continued improvements in treatment strategies that
successfully suppress viral load and contribute to
lower likelihood of transmission.[4] As we have con-
sidered other potential explanations for this observa-
tion, selection bias seemed to be less likely based on
sampling coverage in relation to time and the inclu-
sion of different risk groups and demographic cate-
gories. Also the effect of varying proportions of non-
B subtypes/CRFs appeared to be marginal, since we
found no significant change in proportions between B
and non-B subtypes/CRFs over the study period.
From 2000 and onwards, the prevalence of TDR
appeared to be stabilizing similar to the results
reported in other European countries.[24–26,28,29]
Despite lacking statistical significance, the finding
that TDR was more prevalent among patients who
were born in Iceland and reported infection in the
country might be the consequence of the fact that
access to widespread ART was established early in
Iceland, similar to other European and North
American countries. The same reason could explain
the higher prevalence of TDR among patients
infected with subtype B compared to other HIV-1
genetic variants that dominate in countries where
widespread ART was introduced later in the course
of HIV-1 epidemic.[30,31]
An interesting finding of our study was that a
majority of thymidine analogue 215 revertant
mutants circulated among MSM and HET in
Iceland between 1997 and 2008 with an estimated
median time to the most recent common ancestor
of this cluster dating back to 1989. The domestic
nature of the TDR cluster was confirmed previously
using phylogenetic analysis with similar reference
GenBank sequences obtained through BLAST.[3]
The likely explanation for the spread of such mutants
is the suboptimal AZT-based therapy during late
1980s and early 1990s, in contrast to the later shift
towards tenofovir-based combination regimens.
[32,33] This observation of domestic spread of TDR
highlights the need for continued surveillance to
guide the management of HIV-1 infected patients
and to limit the spread of such mutant variants.
Previous reports in other European countries
described the same mutation (T215C/D) circulating
domestically.[34,35] The ability of these mutants to
be established in transmission chains might be
ascribed to their weak effect on the replicative fitness
of the virus.[36,37]
Study limitations
Since the accurate times of infection in all patients
were unknown, we considered the Icelandic samples
to represent a sero-prevalent cohort. This is an inevi-
table caveat in most clinical settings since patients are
diagnosed at various stages of infection. Another
limitation is that the HIV-1 sequences analysed
were generated based on the Sanger population
sequencing method, and thus minor virus popula-
tions might have escaped detection.[38]
Conclusions
In conclusion, we conducted our investigation on the
basis of WHO recommendations for ARV drug resis-
tance surveillance. These results can be valuable in
contributing to successful management of HIV-1
infected patients. The results of our study also give
useful insights about the effectiveness of the past mea-
sures of control and management of these infections.
Our findings highlight the importance of continuously
monitoring the emergence of ARV resistant mutants in
a systematic, prospective manner, to prevent or limit
the spread of such mutants which can hinder effective
management of HIV-1. Thus, routine baseline HIV-1
genotypic resistance testing in newly diagnosed HIV-
infected individuals in the country is recommended to
disclose TDR at an early stage which can help to
optimize the management of the patients.
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